tazobactam has been researched along with Hospital Acquired Pneumonia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Candel, FJ; González Del Castillo, J; Julián Jiménez, A; Matesanz, M | 1 |
| Bassetti, M; Cattelan, A; Giacobbe, DR; Mussini, C; Vena, A | 1 |
| Bisanti, A; Diaz, E; Martin-Loeches, I; Rodriguez, A | 1 |
| Bruno, C; Carmelitano, P; Castanheira, M; De Anda, C; Huntington, JA; Johnson, MG; Motyl, M; Rhee, EG; Yu, B | 1 |
| Bruno, CJ; Butterton, JR; Huntington, JA; Jensen, EH; Kivistik, Ü; Kollef, MH; Martin-Loeches, I; Nováček, M; Réa-Neto, Á; Rhee, EG; Shime, N; Timsit, JF; Wolf, DJ; Wunderink, RG; Yu, B | 1 |
1 review(s) available for tazobactam and Hospital Acquired Pneumonia
| Article | Year |
|---|---|
Ceftolozane-tazobactam in nosocomial pneumonia.
Topics: Adult; Cephalosporins; Cross Infection; Healthcare-Associated Pneumonia; Humans; Pseudomonas Infections; Tazobactam | 2022 |
2 trial(s) available for tazobactam and Hospital Acquired Pneumonia
| Article | Year |
|---|---|
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cephalosporins; DNA, Bacterial; Double-Blind Method; Drug Resistance, Bacterial; Healthcare-Associated Pneumonia; Humans; Meropenem; Multicenter Studies as Topic; Multilocus Sequence Typing; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Tazobactam; Treatment Outcome | 2021 |
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Double-Blind Method; Equivalence Trials as Topic; Female; Healthcare-Associated Pneumonia; Humans; Logistic Models; Male; Meropenem; Middle Aged; Pneumonia, Bacterial; Retrospective Studies; Tazobactam | 2021 |
2 other study(ies) available for tazobactam and Hospital Acquired Pneumonia
| Article | Year |
|---|---|
Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Cross Infection; Healthcare-Associated Pneumonia; Humans; Pharmaceutical Preparations; Polymyxins; Pseudomonas aeruginosa; Tazobactam; Treatment Outcome | 2020 |
Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Healthcare-Associated Pneumonia; Humans; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |